Based on the aforementioned, MEG3’s tumor-suppressor role in genitourinary cancers positions it as a promising biomarker for early diagnosis and prognosis, while also opening exciting avenues for translating laboratory findings into clinical applications. This evidence concerns the gene MEG3 and urogenital neoplasm.